Max Brenner
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$3.2MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $3.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 15, 2023 | NIH | SBIR Phase I eCIRP-Neutralizing mAb for Acute Lung Injury in Sepsis | $130K | THERASOURCE, LLC |
| Jun 1, 2022 | NIH | SBIR Phase I eCIRP-Neutralizing mAb for Acute Lung Injury in Sepsis | $260K | THERASOURCE, LLC |
| Jul 30, 2021 | NIH | SBIR Phase II rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock | $986K | THERASOURCE, LLC |
| Jun 24, 2020 | NIH | SBIR Phase II rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock | $506K | THERASOURCE, LLC |
| May 1, 2020 | NIH | SBIR Phase I A New Therapy for Acute Kidney Injury | $140K | THERASOURCE, LLC |
| Aug 30, 2019 | NIH | SBIR Phase II rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock | $506K | THERASOURCE, LLC |
| May 22, 2019 | NIH | SBIR Phase I A New Therapy for Acute Kidney Injury | $300K | THERASOURCE, LLC |
| Mar 14, 2018 | NIH | STTR Phase I Preclinical Development of a Novel Small Molecule Drug for Sepsis | $111K | THERASOURCE, LLC |
| Mar 28, 2017 | NIH | STTR Phase I Preclinical Development of a Novel Small Molecule Drug for Sepsis | $222K | THERASOURCE, LLC |
Peer ranks
Federal funding#568
Awards as PI#151
Patents#273
Companies
- THERASOURCE, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.